Edit
Viela Bio (NASDAQ:VIE)
http://vielabio.com/Last activity: 01.02.2021
Active - Reference to Viela Bio
Viela Bio is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. The team is comprised of passionate, talented, world-class leaders with diverse experience in the autoimmune disease space and our research focuses on well-established critical biological pathways shared across multiple indications. The team believe that the approach – which targets the underlying molecular pathogenesis of the disease – enables Viela Bio to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple indications for each of their product candidates.
Location: United States, Maryland, Gaithersburg
Employees: 51-200
Total raised: $600M
Founded date: 2017
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.06.2019 | Series B | $350M | - |
| 01.03.2018 | Series A | $250M | - |
Mentions in press and media 14
| Date | Title | Description |
| 01.02.2021 | Gaithersburg’s Viela Bio is set to be acquired for $3.05B | Gaithersburg, Maryland-based Viela Bio is set to be acquired by Dublin-based biopharmaceutical company Horizon Therapeutics for $3.05 billion. Launched in February 2018, the biotech startup develops treatments for severe inflammation and au... |
| 20.06.2019 | Gaithersburg-based Viela Bio closed on a $75M Series B funding round | Gaithersburg, Md.-based Viela Bio announced that it has closed on a $75 million Series B funding round. The financing round was led by HBM Healthcare Investments, with additional new investments from Viking Global Investors, Cormorant Asset... |
| 18.06.2019 | How Viela Bio's Drug Development Landed $350M in Funding in 16 Months | Just 16 months into its existence, a local biotech startup has investors swarming. Gaithersburg, Md.-based Viela Bio has completed a $75 million Series B funding round, bringing its total raised since launching to more than $350 million. Th... |
| 18.06.2019 | Temasek backs $75m Series B for US-based Viela Bio | Premium US-based clinical-stage biotechnology company Viela Bio has raised $75 million in a Series B financing round backed by existing investor Singapore’s state-owned investment firm Temasek Holdings, according to a statement. Continue re... |
| 17.06.2019 | Viela Bio Closes $75M Series B Financing | Viela Bio, a Gaithersburg, MD-based clinical-stage biotechnology company, completed a $75m in Series B funding. The round, which brought the total capital raised since launch in February 2018 to more than $300m, was led by HBM Healthcare In... |
| 17.06.2019 | HBM Healthcare Investments announces investment of USD 20 million in Viela Bio | Viela Bio, a privately held biotechnology company, today announced the successful completion of a USD 75 million private placement. HBM Healthcare Investments led the financing round and invested USD 20 million. Additional new investors inc... |
| 17.06.2019 | Viela Bio Closes $75M Series B Financing | GAITHERSBURG, Md.--(BUSINESS WIRE)--Viela Bio today announced the successful completion of a $75 million private placement of its Series B preferred stock, bringing the total capital raised since the Company's launch in February 2018 to mor... |
| 01.03.2018 | US biotech firm Viela Bio raises $250m in Temasek-backed Series A | Premium US-headquartered Viela Bio, an inflammation and autoimmune biotech spinout of AstraZeneca, has raised $250 million in Series A funding backed by Singapore state-owned investment firm Temasek. Continue reading this story with a subsc... |
| 01.03.2018 | Term Sheet — Thursday, March 1 | REBEL IPO Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop But of course, the faster and cheaper route comes with risks. As it notes in its prospectus, there are no safeguards to protec... |
| 28.02.2018 | AstraZeneca spins out 6 drugs and an R&D group into Viela Bio, which emerges with a pivotal program and $250M | AstraZeneca $AZN has culled its pipeline of preclinical through mid-stage anti-inflammatory/autoimmune drugs at its big MedImmune subsidiary in Gaithersburg, MD and spun out six programs into a new startup called Viela Bio... |
Show more